Limbal Stem-cell Deficiency clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Stem Cell Therapy for Limbal Stem Cell Deficiency
open to eligible people ages 18 years and up
This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).
at UCLA
Our lead scientists for Limbal Stem-cell Deficiency research studies include Sophie Deng.
Last updated: